{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:58:39Z","timestamp":1792425519335,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Treating complicated urinary tract infections (cUTIs) caused by ESBL-producing Enterobacterales represents a significant clinical challenge. The present study was thus developed to explore the relative efficacy of \u03b2-lactam\/\u03b2-lactamase inhibitors (BLBLIs) and carbapenems for the treatment of hospitalized patients suffering from cUTIs caused by BLBLI-susceptible ceftriaxone-non-susceptible Enterobacterales.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from 557 patients from four Chinese teaching hospitals diagnosed with cUTIs caused by ceftriaxone-non-susceptible Enterobacterales from January 2017 to May 2022 were retrospectively assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>The 30 day rate of treatment failure, defined by unresolved symptoms or mortality, was 10.4% (58\/557). Independent predictors of 30 day treatment failure included immunocompromised status, bacteraemia, septic shock, lack of infection source control and appropriate empirical treatment. When data were controlled for potential confounding variables, BLBLI treatment exhibited a comparable risk of 14 day (OR 1.61, 95% CI 0.86\u20133.00, P\u200a=\u200a0.133) and 30 day treatment failure (OR 1.45, 95% CI 0.66\u20133.15, P\u200a=\u200a0.354) relative to carbapenem treatment for the overall cohort of patients. In contrast, BLBLI treatment in immunocompromised patients was associated with an elevated risk of both 14 day (OR 3.18, 95% CI 1.43\u20137.10, P\u200a=\u200a0.005) and 30 day treatment failure (OR 3.06, 95% CI 1.07\u20138.80, P\u200a=\u200a0.038) relative to carbapenem treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results suggested that carbapenem treatment may be superior to BLBLI treatment for immunocompromised patients suffering from cUTIs caused by ceftriaxone-non-susceptible Enterobacterales species. However, these results will need to be validated in appropriately constructed randomized controlled trials to ensure appropriate patient treatment.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkac448","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T10:14:17Z","timestamp":1674555257000},"page":"710-718","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of the relative efficacy of \u03b2-lactam\/\u03b2-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational cohort study"],"prefix":"10.1093","volume":"78","author":[{"given":"Liang","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Nanjing Lishui People\u2019s Hospital, Zhongda Hospital Lishui Branch, Southeast University , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liyang People\u2019s Hospital, Liyang Branch Hospital of Jiangsu Province Hospital , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Jie","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Nanjing Medical University , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Nanjing Medical University , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo-Chen","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Nanjing Medical University , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Yu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Nanjing Medical University , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wen","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Nanjing Medical University , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Nanjing Medical University , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3147-5688","authenticated-orcid":false,"given":"Xiao-Pu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Geriatric Gastroenterology, The First Affiliated Hospital of Nanjing Medical University , Nanjing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"2023030208085858100_","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.695027","article-title":"Epidemiology of extended-spectrum beta-lactamase and carbapenemase-producing Enterobacterales in the greater Mekong Subregion: a systematic-review and meta-analysis of risk factors associated with extended-spectrum beta-lactamase and carbapenemase isolation","volume":"12","author":"Singh","year":"2021","journal-title":"Front Microbiol"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106633","article-title":"Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections","volume":"60","author":"Kanj","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.meegid.2018.04.005","article-title":"Current epidemiology, genetic evolution and clinical impact of extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"61","author":"Chong","year":"2018","journal-title":"Infect Genet Evol"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012\u20132017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jhin.2015.01.008","article-title":"Multidrug-resistant Gram-negative bacteria: a product of globalization","volume":"89","author":"Hawkey","year":"2015","journal-title":"J Hosp Infect"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/dkw372","article-title":"High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in community-onset bloodstream infections in China","volume":"72","author":"Quan","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jinf.2011.02.009","article-title":"Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria","volume":"62","author":"Chen","year":"2011","journal-title":"J Infect"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1128\/AAC.01808-09","article-title":"Susceptibility of Gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007\u20132008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)","volume":"54","author":"Hoban","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1469-0691.2000.00107.x","article-title":"Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum \u03b2-lactamases (ESBLs)","volume":"6","author":"Paterson","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"h6420","DOI":"10.1136\/bmj.h6420","article-title":"Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications","volume":"352","author":"Iredell","year":"2016","journal-title":"BMJ"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3201\/eid2603.191230","article-title":"Acquisition of plasmid with carbapenem-resistance gene blaKPC2 in hypervirulent Klebsiella pneumoniae, Singapore","volume":"26","author":"Chen","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam versus meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106410","article-title":"Non-carbapenem \u03b2-lactam\/\u03b2-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review","volume":"58","author":"Zhang","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.diagmicrobio.2014.07.006","article-title":"Carbapenems and piperacillin\/tazobactam for the treatment of bacteremia caused by extended-spectrum \u03b2-lactamase-producing Proteus mirabilis","volume":"80","author":"Tsai","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00365-16","article-title":"A multinational, preregistered cohort study of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"60","author":"Gutierrez-Gutierrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/cid\/cit017","article-title":"Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam","volume":"56","author":"Dudley","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00213-21","article-title":"Overview of changes to the Clinical and Laboratory Standards Institute performance standards for antimicrobial susceptibility testing, M100, 31st edition","volume":"59","author":"Humphries","year":"2021","journal-title":"J Clin Microbiol"},{"key":"2023030208085858100_","article-title":"Clinical effectiveness of beta-lactams versus fluoroquinolones as empirical therapy in patients with diabetes mellitus hospitalized for urinary tract infections: a retrospective cohort study","volume":"17","author":"Tang","year":"2022","journal-title":"PLoS One"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.chest.2020.05.598","article-title":"Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies","volume":"158","author":"Ramirez","year":"2020","journal-title":"Chest"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00698-21","article-title":"Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Enterobacterales","volume":"65","author":"Chen","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/pathogens11030356","article-title":"Antimicrobial resistance in Enterobacterales recovered from urinary tract infections in France","volume":"11","author":"Farfour","year":"2022","journal-title":"Pathogens"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jinf.2021.06.004","article-title":"Etiology and prevalence of ESBLs in adult community-onset urinary tract infections in East China: a prospective multicenter study","volume":"83","author":"Quan","year":"2021","journal-title":"J Infect"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106535","article-title":"Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019","volume":"59","author":"Karlowsky","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237365","article-title":"Treatment duration of complicated urinary tract infections by extended-spectrum beta-lactamases producing Enterobacterales","volume":"15","author":"Alvarez Otero","year":"2020","journal-title":"PLoS One"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ccc.2013.03.014","article-title":"Urinary tract infection","volume":"29","author":"Nicolle","year":"2013","journal-title":"Crit Care Clin"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s00018-003-2225-6","article-title":"Pathogen, host and environmental factors contributing to the pathogenesis of listeriosis","volume":"60","author":"Roberts","year":"2003","journal-title":"Cell Mol Life Sci"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/microbiolspec.DMIH2-0026-2016","article-title":"Overview of infections in the immunocompromised host","volume":"4","author":"Dropulic","year":"2016","journal-title":"Microbiol Spectr"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1208623","article-title":"Severe sepsis and septic shock","volume":"369","author":"Angus","year":"2013","journal-title":"N Engl J Med"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jmii.2011.12.009","article-title":"Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia","volume":"45","author":"Huang","year":"2012","journal-title":"J Microbiol Immunol Infect"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153696","article-title":"Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"11","author":"Ng","year":"2016","journal-title":"PLoS One"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac034","article-title":"Efficacy of noncarbapenem \u03b2-lactams compared to carbapenems for extended-spectrum \u03b2-lactamase-producing Enterobacterales urinary tract infections","volume":"9","author":"Anderson","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum \u03b2-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-clinpsy-032816-045030","article-title":"Accounting for confounding in observational studies","volume":"16","author":"D\u2019Onofrio","year":"2020","journal-title":"Annu Rev Clin Psychol"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.770518","article-title":"Limitations of antibiotic MIC-based PK-PD metrics: looking back to move forward","volume":"12","author":"Landersdorfer","year":"2021","journal-title":"Front Pharmacol"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.00135-13","article-title":"Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-\u03b2-lactamase-producing Escherichia coli","volume":"57","author":"Retamar","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2023030208085858100_","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040210","article-title":"Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)","volume":"11","author":"Bitterman","year":"2021","journal-title":"BMJ Open"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/3\/710\/49376314\/dkac448.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/3\/710\/49376314\/dkac448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T18:57:21Z","timestamp":1679165841000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/3\/710\/7000149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,24]]},"published-print":{"date-parts":[[2023,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac448","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,2]]},"published":{"date-parts":[[2023,1,24]]}}}